Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombocytopenic, Idiopathic | 15 | 2026 | 65 | 5.150 |
Why?
|
| Thrombocytopenia | 6 | 2026 | 219 | 1.370 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 4 | 2026 | 29 | 1.170 |
Why?
|
| Anemia, Megaloblastic | 2 | 2019 | 3 | 1.160 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2026 | 148 | 1.100 |
Why?
|
| Transportation | 1 | 2024 | 27 | 0.860 |
Why?
|
| Autoimmune Diseases | 3 | 2023 | 265 | 0.850 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 209 | 0.780 |
Why?
|
| Eosinophilia | 2 | 2022 | 110 | 0.760 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 166 | 0.730 |
Why?
|
| Thiamine Deficiency | 1 | 2019 | 3 | 0.600 |
Why?
|
| Hydroxocobalamin | 1 | 2018 | 8 | 0.570 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 344 | 0.560 |
Why?
|
| Child, Preschool | 20 | 2026 | 14948 | 0.560 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 49 | 0.540 |
Why?
|
| Receptors, Thrombopoietin | 3 | 2026 | 35 | 0.520 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 156 | 0.520 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1828 | 0.510 |
Why?
|
| Infant | 15 | 2026 | 13230 | 0.500 |
Why?
|
| Child | 28 | 2026 | 26105 | 0.500 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 192 | 0.500 |
Why?
|
| Adolescent | 20 | 2026 | 20732 | 0.480 |
Why?
|
| Osteosarcoma | 1 | 2019 | 275 | 0.480 |
Why?
|
| Rho(D) Immune Globulin | 3 | 2025 | 14 | 0.440 |
Why?
|
| Exercise | 3 | 2025 | 862 | 0.420 |
Why?
|
| Thrombosis | 1 | 2019 | 499 | 0.420 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 470 | 0.420 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 851 | 0.380 |
Why?
|
| Disease Progression | 1 | 2018 | 2191 | 0.360 |
Why?
|
| Male | 25 | 2026 | 64470 | 0.350 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 891 | 0.330 |
Why?
|
| Humans | 37 | 2026 | 130432 | 0.320 |
Why?
|
| Female | 24 | 2026 | 70362 | 0.320 |
Why?
|
| Platelet Count | 6 | 2026 | 139 | 0.320 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2025 | 332 | 0.320 |
Why?
|
| Prognosis | 6 | 2025 | 4861 | 0.280 |
Why?
|
| Chronic Disease | 4 | 2026 | 1239 | 0.260 |
Why?
|
| Blood Platelets | 2 | 2026 | 315 | 0.230 |
Why?
|
| Benzoates | 1 | 2025 | 25 | 0.230 |
Why?
|
| Hydrazines | 1 | 2025 | 28 | 0.230 |
Why?
|
| Thiophenes | 1 | 2025 | 68 | 0.230 |
Why?
|
| Thiazoles | 1 | 2025 | 112 | 0.220 |
Why?
|
| Missouri | 1 | 2024 | 43 | 0.220 |
Why?
|
| Immunoglobulins | 1 | 2024 | 154 | 0.210 |
Why?
|
| Models, Statistical | 1 | 2026 | 482 | 0.200 |
Why?
|
| Social Stigma | 1 | 2024 | 78 | 0.200 |
Why?
|
| Transgender Persons | 1 | 2024 | 67 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2025 | 355 | 0.190 |
Why?
|
| Leukopenia | 1 | 2023 | 43 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2026 | 17522 | 0.190 |
Why?
|
| Primary Myelofibrosis | 1 | 2023 | 51 | 0.180 |
Why?
|
| Thrombocytosis | 1 | 2022 | 34 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2026 | 12845 | 0.180 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 52 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 218 | 0.170 |
Why?
|
| Adult | 9 | 2024 | 31124 | 0.170 |
Why?
|
| Neutropenia | 2 | 2019 | 203 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 156 | 0.160 |
Why?
|
| HIV Infections | 2 | 2022 | 2034 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 227 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 228 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 208 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2026 | 774 | 0.150 |
Why?
|
| Orchiectomy | 1 | 2019 | 45 | 0.150 |
Why?
|
| Coombs Test | 1 | 2019 | 6 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 3798 | 0.150 |
Why?
|
| Fatigue | 1 | 2020 | 192 | 0.150 |
Why?
|
| Genotype | 1 | 2024 | 2590 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2019 | 120 | 0.140 |
Why?
|
| Anemia | 1 | 2022 | 352 | 0.140 |
Why?
|
| Hematologic Tests | 1 | 2018 | 36 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 92 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 111 | 0.140 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2018 | 43 | 0.140 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 185 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 80 | 0.140 |
Why?
|
| Failure to Thrive | 1 | 2018 | 87 | 0.140 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 108 | 0.140 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 178 | 0.130 |
Why?
|
| Genetic Variation | 1 | 2024 | 1541 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 104 | 0.130 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2017 | 6 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2018 | 191 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 142 | 0.130 |
Why?
|
| Histiocytes | 1 | 2017 | 17 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2019 | 363 | 0.130 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2017 | 32 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 106 | 0.130 |
Why?
|
| Health Care Costs | 2 | 2018 | 406 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 82 | 0.120 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 77 | 0.120 |
Why?
|
| Heart Atria | 1 | 2019 | 336 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 713 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2018 | 291 | 0.120 |
Why?
|
| Rituximab | 1 | 2017 | 171 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 546 | 0.120 |
Why?
|
| Hydroxyurea | 1 | 2016 | 88 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1216 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2826 | 0.110 |
Why?
|
| Bacteremia | 1 | 2019 | 429 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2017 | 356 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2018 | 400 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 162 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 504 | 0.110 |
Why?
|
| Sports | 2 | 2025 | 67 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 306 | 0.100 |
Why?
|
| Disease Management | 3 | 2024 | 555 | 0.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 229 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3406 | 0.100 |
Why?
|
| Neoplasms | 2 | 2018 | 2973 | 0.100 |
Why?
|
| Lamivudine | 2 | 2022 | 29 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2826 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1287 | 0.090 |
Why?
|
| Glucocorticoids | 2 | 2025 | 346 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3030 | 0.080 |
Why?
|
| Physicians, Family | 1 | 2009 | 37 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2022 | 3354 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2018 | 3676 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 112 | 0.070 |
Why?
|
| Middle Aged | 3 | 2024 | 28393 | 0.070 |
Why?
|
| Risk Factors | 4 | 2026 | 10949 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 266 | 0.060 |
Why?
|
| Thrombopoietin | 1 | 2026 | 30 | 0.060 |
Why?
|
| Mutation | 1 | 2019 | 6092 | 0.060 |
Why?
|
| North America | 1 | 2026 | 255 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 390 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 706 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5155 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2025 | 708 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2024 | 224 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 227 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2022 | 247 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2025 | 488 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 250 | 0.040 |
Why?
|
| Eosinophils | 1 | 2022 | 120 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2025 | 6429 | 0.040 |
Why?
|
| Prednisolone | 1 | 2021 | 72 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2021 | 94 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 517 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 705 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2026 | 4033 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 213 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 290 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 16 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2017 | 31 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 84 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 304 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 190 | 0.030 |
Why?
|
| United States | 2 | 2025 | 11871 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1486 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 225 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 2072 | 0.030 |
Why?
|
| Young Adult | 2 | 2025 | 9997 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 899 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 547 | 0.020 |
Why?
|
| Prevalence | 1 | 2020 | 2684 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 1445 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2896 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 2112 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 1117 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 4475 | 0.020 |
Why?
|
| Arkansas | 1 | 2009 | 58 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 277 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3644 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8530 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2576 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 4669 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 20882 | 0.010 |
Why?
|